{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:56:37Z","timestamp":1777884997570,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Comparative Immunology, Microbiology and Infectious Diseases"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.cimid.2007.11.004","type":"journal-article","created":{"date-parts":[[2008,2,20]],"date-time":"2008-02-20T16:19:48Z","timestamp":1203524388000},"page":"9-19","source":"Crossref","is-referenced-by-count":29,"title":["Ovine anti-rabies antibody production and evaluation"],"prefix":"10.1016","volume":"32","author":[{"given":"EL-Rashdy M.","family":"Redwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr EL","family":"Hanafy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawal Abd","family":"EL-Baky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sobhy M.A.","family":"Sallam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cimid.2007.11.004_bib1","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.cimid.2007.11.004_bib2","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jama.1965.03090050035009","article-title":"Incidence of reactions following administration of anti-rabies serum: a study of 526 cases","volume":"193","author":"Karliner","year":"1965","journal-title":"J Am Med Associ"},{"key":"10.1016\/j.cimid.2007.11.004_bib3","series-title":"Therapeutics antibodies","first-page":"1","article-title":"An introduction to the clinical applications of antibodies","author":"Landon","year":"1995"},{"issue":"8570","key":"10.1016\/j.cimid.2007.11.004_bib4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(87)91885-X","article-title":"Safety of equine rabies immune globulin","volume":"2","author":"Wilde","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.cimid.2007.11.004_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0264-410X(89)90003-0","article-title":"Adverse effects of equine rabies immune globulin","volume":"7","author":"Wilde","year":"1989","journal-title":"Vaccine"},{"key":"10.1016\/j.cimid.2007.11.004_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4269\/ajtmh.1990.42.175","article-title":"Equine rabies immune globulin: a product with an undeserved poor reputation","volume":"42","author":"Wilde","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cimid.2007.11.004_bib7","unstructured":"WHO Expert Committee on Biological Standardization. Forty-third report. Geneva. Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives. World Health Organization; 1984. WHO Tech. Report Ser. No. 840, annex 2."},{"key":"10.1016\/j.cimid.2007.11.004_bib8","unstructured":"WHO Expert Committee on Rabies. Eighth report. Geneva, World Health Organization; 1992. WHO Tech. Report Ser. No. 824, annex 2."},{"key":"10.1016\/j.cimid.2007.11.004_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cimid.2005.01.001","article-title":"Production and purification of ovine anti-tetanus antibody","volume":"28","author":"Redwan","year":"2005","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.cimid.2007.11.004_bib10","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0735-1097(10)80170-6","article-title":"Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study","volume":"17","author":"Hickey","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cimid.2007.11.004_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/15321810600861993","article-title":"Comparison between therapeutic antitoxin F(ab)2 fractionated with ammonium sulfate and caprylic acid","volume":"27","author":"Redwan","year":"2006","journal-title":"J Immunoassay Immunochem"},{"key":"10.1016\/j.cimid.2007.11.004_bib12","first-page":"321","article-title":"Production in Vero cells of an inactivated rabies vaccine from strain FRV\/K for animal and human use","volume":"31","author":"El-karamany","year":"1987","journal-title":"Acta Virol"},{"key":"10.1016\/j.cimid.2007.11.004_bib13","first-page":"443","article-title":"A simple method of estimating 50% end point","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"key":"10.1016\/j.cimid.2007.11.004_bib14","first-page":"157","article-title":"Biological activity of Tubercle Bacilli (BCG) and its related immunogenicity","volume":"6","author":"Mohamed","year":"1997","journal-title":"Egyptian J Med Microbiol"},{"key":"10.1016\/j.cimid.2007.11.004_bib15","first-page":"97","article-title":"Biological and hematological studies post rabies virus infection: clinical view","volume":"9","author":"Mohamed","year":"1998","journal-title":"J Union Arab Biol Cairo"},{"key":"10.1016\/j.cimid.2007.11.004_bib16","first-page":"147","article-title":"Experimental preparation of Vero cell rabies vaccine and related anti-rabies immunoglobulin in horses for human use","volume":"11","author":"Mohamed","year":"2002","journal-title":"Egyptian J Med Microbiol"},{"key":"10.1016\/j.cimid.2007.11.004_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0092-1157(85)80047-0","article-title":"A collaborative study to establish an International Standard Rabies immunoglobulin of human origin","volume":"13","author":"Fitzgerald","year":"1985","journal-title":"J Biol Stand"},{"key":"10.1016\/j.cimid.2007.11.004_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1045-1056(03)00059-9","article-title":"Antibody response to purified chick embryo cell vaccine in equines for production of equine rabies immune globulin","volume":"31","author":"Goel","year":"2003","journal-title":"Biologicals"},{"key":"10.1016\/j.cimid.2007.11.004_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/jcp.33.2.180","article-title":"A regional programme to collect plasma for preparation of human immunoglobulin anti-rabies","volume":"33","author":"Crawford","year":"1980","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cimid.2007.11.004_bib20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0264-410X(98)00314-4","article-title":"A study of human rabies immune globulin manufactured by the Thai Red Cross","volume":"17","author":"Chantanakajornfung","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.cimid.2007.11.004_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1271\/bbb.57.450","article-title":"Productivity and some properties of egg yolk antibody (IgY) against human rotavirus compared with rabbit IgG","volume":"57","author":"Hatta","year":"1993","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.cimid.2007.11.004_bib22","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1016\/j.vaccine.2004.11.071","article-title":"Production of rabies neutralizing antibody in hen's eggs using a part of the G protein expressed in Escherichia coli","volume":"23","author":"Motoi","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.cimid.2007.11.004_bib23","series-title":"Envenomings and Their Treatments","first-page":"173","article-title":"Development of novel antivenoms based on specific ovine Fab","author":"Landon","year":"1996"},{"key":"10.1016\/j.cimid.2007.11.004_bib24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.toxicon.2005.08.004","article-title":"Factors associated with adverse reactions induced by caprylic acid-fractionated whole IgG preparations: comparison between horse, sheep and camel IgGs","volume":"46","author":"Herrera","year":"2005","journal-title":"Toxicon"}],"container-title":["Comparative Immunology, Microbiology and Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147957107001270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147957107001270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T04:57:29Z","timestamp":1557291449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147957107001270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0147957107001270"],"URL":"https:\/\/doi.org\/10.1016\/j.cimid.2007.11.004","relation":{},"ISSN":["0147-9571"],"issn-type":[{"value":"0147-9571","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}